EUCTR2020-002344-23-FR进行中（未招募）1 期
Regorafenib in combination with metronomic cyclophosphamide, capecitabine, and low-dose aspirin in metastatic colorectal cancer carcinomaAn open-label phase II - REPROGRAM-01
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 49
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Patients with histologically proven metastatic colorectal cancer in progression after previous standard treatments (5FU, CPT11, oxaliplatin, anti-VEGF and anti-EGFR therapy if KRAS and NRAS WT), or not considered as candidate for these treatments
- •2.Life expectancy of at least 3 months
- •3.Female or male with age >18 years old
- •4.Performance status = 0 or 1 (Annex 1)
- •5.Measurable disease defined according to RECIST v1.1 guidelines (scanner or MRI) (Annex 2)
- •6.Adequate bone marrow, liver and renal functions.
- •a.Haemoglobin = 9 g/dL; absolute neutrophil count (ANC) = 1.5 x 109/L; platelets = 100 x 109/L
- •b.Total serum bilirubin = 1.5 times upper normal value (ULN), serum alkaline phosphatase < 5 times ULN, aminotransferases (AST/ALT) = 3 × ULN in absence of hepatic metastasis or = 5 if presence of hepatic lesions
- •c.Cockcroft glomerular filtration rate > 50 ml/min
- •d.Proteinuria <2+ (dipstick urinalysis) or =1g/24hour
- •7.Imaging target greater than one cm must be visible on CT,
- •8.No contraindication to Iodine contrast media injection during CT
- •9.For female patients of childbearing potential, negative pregnancy test within 14 days before starting the study drug. Men and women are required to use adequate birth control during the study (when applicable),
- •10.Signed and dated informed consent,
- •11.Ability to comply with the study protocol, in the Investigator’s judgment.
- •12.Registration in a national health care system (CMU included).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 19
排除标准
- •Non-eligible to a clinical trial:
- •1.Diagnosis of additional malignancy within 2 years prior to the inclusion (exception of curatively treated basal cell carcinoma of the skin and/or curatively resected in situ cervical cancer),
- •2.Current participation in a study of an investigational agent or in the period of exclusion
- •3.Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before inclusion in the trial ;
- •4.Patient under judicial protection (curatorship, tutorship) and/or deprived of freedom,
- •Cancer-specific or treatment-specific exclusion criteria:
- •5.Planned surgical procedure within the first month of treatment or any procedure that might change the timing of regorafenib administration during the first month of treatment,
- •6.Previous exposition to regorafenib
- •7.Previous exposition to other anti-angiogenic treatment than bevacizumab and aflibercept
- •8.Complete deficit in dihydropyrimidine deshydrogenase (DPD),
- •9.Major surgical procedure, open biopsy or significant traumatic injury within 28 days before start of study medication,
- •10.Pregnant or breast-feeding subjects,
- •11.Congestive Heart Failure = New York Heart Association (NYHA) class 2, unstable angina (anginal symptomatology at rest),
- •12.Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months),
- •13.Myocardal infarction less than 6 months before start of study drug,
- •14.Cardiac arrhythmias requiring anti-arrhythmic therapy (beta-blockers or digoxin are permitted),
- •15.Uncontrolled hypertension (Systolic blood pressure >150 mmHg and/or diastolic pressure >100 mmHg despite optimal medical management), or history of hypertensive crisis, or hypertensive encephalopathy
- •16.Pleural effusion or ascites that causes respiratory compromise (= CTCAE grade 2 dyspnea),
- •17.Ongoing infection >grade 2 CTCAE V5,
- •18.Known History of human immunodeficiency virus (HIV) infection,
- •19.Active hepatitis B or C or chronic hepatitis B or C requiring treatment with antiviral therapy,
- •20.Subjects with seizure disorder requiring medication,
- •21.History of organ allograft,
- •22.Subjects with evidence or history of any bleeding diathesis, irrespective of severity,
- •23.Any haemorrhage or bleeding event = CTCAE Grade 3 within 4 weeks prior to the start of study medication,
- •24.Serious, Non-healing wound, active ulcer or untreated bone fracture,
- •25.History of abdominal fistula, GI perforation, intra-abdominal abscess or active GI bleeding within 6 months prior to inclusion,
- •26.Dehydration CTCAE v4 grade =1,
- •27.Known hypersensitivity to any of the study drugs, study drug classes or excipient in the formulation,
- •28.Interstitial lung disease with ongoing signs or symptoms,
- •29.Persistent proteinuria of CTCAE Grade 3 (>3.5 g/24 hours),
- •30.Subject unable to swallow oral medications,
- •31.Any malabsorption condition, unresolved toxicity higher than CTCAE (V4) Grade 1 attributed to any prior therapy/procedure excluding alopecia, hypothyroidism and oxaliplatin induced neuropathy = Grade 2,
- •32.Systemic anticancer therapy including cytotoxic therapy, signal transduction inhibitors, immunotherapy, and hormonal therapy during this trial or within 3 weeks,
- •33.Treatment with any other investigational medicinal product within 28 days prior to study entry, EXCEPT for ASPIRIN,
- •34.Chronic treatment with drug potentially interacti
研究者
相似试验
招募中
1 期
CARE : Impact of Regorafenib in combination with multimodal metronomic chemotherapy (cyclophosphamide, capecitabine, and low-dose aspirin) on progression-free survival compared with standard Regorafenib for the treatment of chemo-resistant metastatic colorectal cancersMetastatic colorectal cancerMedDRA version: 21.0Level: PTClassification code: 10052358Term: Colorectal cancer metastatic Class: 100000004864CTIS2023-509761-21-00Centre Hospitalier Regional Universitaire174
进行中（未招募）
1 期
_advanced Biliary Tract CancerMedDRA version: 17.0Level: PTClassification code 10055111Term: Biliary cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-004385-34-FRInstitut régional du Cancer - Montpellier - Val d'Aurelle87
进行中（未招募）
1 期
Assessment of the effects of an oral chemotherapy (Regorafenib) after failure of previous treatments for non-operable patients suffering from a particular type of biliary tract cancer.ocally advanced (non resectable) and metastatic histologically proven intra-hepatic or hilum cholangiocarcinoma + histologically proven metastatic extra-hepatic cholangiocarcinoma (common bile duct and gallbladder), progressing after gemcitabine-CDDP (or gemcitabine-oxaliplatin) or after gemcitabine alone followed or preceded by platinum-based chemotherapyEUCTR2012-005626-30-BECUB Erasme Hospital66
招募中
1 期
Phase Ib study of the combination of regorafenib with conventional chemotherapy for the treatment of newly diagnosed patients with multimetastatic Ewing sarcoma - REGO-INTER-EWING1ewly diagnosed patients with metastatic (other than lung/pleura metastases only) Ewing sarcomaCTIS2023-503322-39-00Institut Gustave Roussy29
招募中
2 期
Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal CancerMetastatic Colorectal CancerNCT05462613Centre Hospitalier Universitaire de Besancon446